Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature
Autor: | Roman G. Shmakov, Sergey Aleshin, Ekaterina Chelysheva, Igor Shokhin, Anna G. Turkina, Evgenia Polushkina, Ghermes G. Chilov |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
Drug
medicine.medical_specialty media_common.quotation_subject chronic myeloid leukaemia pregnancy breastfeeding milk breast milk imatinib nilotinib dasatinib molecular response Cmax Breastfeeding Breast milk Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine hemic and lymphatic diseases medicine media_common Pregnancy business.industry lcsh:RC633-647.5 Imatinib Hematology lcsh:Diseases of the blood and blood-forming organs medicine.disease Dasatinib Infectious Diseases Nilotinib 030220 oncology & carcinogenesis business 030215 immunology medicine.drug |
Zdroj: | Mediterranean Journal of Hematology and Infectious Diseases, Vol 10, Iss 1, Pp e2018027-e2018027 (2018) |
ISSN: | 2035-3006 |
Popis: | Breastfeeding in patients with chronic myeloid leukaemia (CML) who take tyrosine kinase inhibitors (TKIs) is not recommended but interruption of TKI treatment may cause the loss of remission. We observed the kinetics of the leukaemic clone in 3 women with CML in accordance with treatment interruptions for pregnancy and breastfeeding. The concentrations of nilotinib and imatinib in maternal milk were measured when the breastfeeding period was over. Nilotinib transfer into human breast milk was demonstrated for the first time and had a maximum concentration (Cmax) 129 ng/ml after 4 hours of the drug intake at a dose of 400 mg. The Cmax of imatinib in maternal milk ranged from 420 to 1411 ng/ml after 4-8 hours of the drug intake at a dose of 400-600 mg. Breastfeeding without TKI treatment may be safe with molecular monitoring, but preferably in those patients with CML who have durable deep molecular response. |
Databáze: | OpenAIRE |
Externí odkaz: |